Clinical and pharmacological considerations for concomitant administration of posaconazole and isavuconazole with letermovir Journal Article


Authors: Terrier, J.; Zanella, M. C.; Masouridi-Levrat, S.; Kronig, I.; Chalandon, Y.; Vernaz, N.; van Delden, C.; Papanicolaou, G.; Neofytos, D.
Article Title: Clinical and pharmacological considerations for concomitant administration of posaconazole and isavuconazole with letermovir
Abstract: We sought in this case-control retrospective study to compare posaconazole and isavuconazole (PCZ and IVC, respectively) plasma trough concentration (Ctrough) levels in high-risk allogeneic hematopoietic cell transplant (HCT) recipients who received letermovir (LET) or not. PCZ/IVC Ctrough levels were not found to be significantly different between cases and controls, as they were 1.31 mg/liter (median) (interquartile range [IQR], 0.90) versus 1.36 mg/liter (IQR, 1.16) (P = 0.31) and 3.20 mg/ liter (IQR, 2.40) versus 2.35 mg/liter (IQR, 1.50) (P = 0.17), respectively. In conclusion, we observed PCZ/IVC Ctrough levels within the expected range and no significant effect of LET coadministration. Copyright © 2021 American Society for Microbiology. All Rights Reserved.
Keywords: retrospective studies; pyridines; antifungal agent; hematopoietic stem cell transplantation; retrospective study; quinazolines; acetic acid; quinazoline derivative; posaconazole; antifungal agents; triazoles; nitriles; nitrile; triazole derivative; pyridine derivative; acetates; therapeutic drug monitoring; letermovir; isavuconazole; allogeneic hematopoietic cell transplant recipients
Journal Title: Antimicrobial Agents and Chemotherapy
Volume: 65
Issue: 6
ISSN: 0066-4804
Publisher: American Society for Microbiology  
Date Published: 2021-06-01
Start Page: e00274-21
Language: English
DOI: 10.1128/aac.00274-21
PUBMED: 33782007
PROVIDER: scopus
PMCID: PMC8316116
DOI/URL:
Notes: Article -- Export Date: 1 July 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors